.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
S3V Vascular Technologies recently reached a major milestone in Indian medical innovation. They announced plans to move their indigenous TAVR system India into preclinical evaluation. This phase will validate the safety and design performance of the balloon-expandable device. Consequently, the company hopes for a commercial launch within the next 18 months.
Transcatheter Aortic Valve Replacement (TAVR) offers a minimally invasive alternative for severe aortic stenosis. Traditionally, patients required open-heart surgery for valve issues. However, clinicians can now replace the valve via a catheter. This method significantly reduces recovery time for high-risk or elderly patients. Furthermore, domestic innovation ensures that the technology meets local clinical needs effectively.
Currently, India performs only 4,000 TAVR procedures annually. Nevertheless, the clinical need exceeds 50,000 cases each year. High costs of imported devices create a significant barrier for many patients. Imported systems usually cost between ₹13 lakh and ₹23 lakh. Therefore, S3V aims to democratize care by providing a high-quality, local alternative. This shift could transform cardiac care delivery across the country.
Q1: What is the main benefit of the S3V TAVR system?
A1: It aims to provide a high-quality, affordable local alternative to expensive imported heart valves, increasing accessibility for Indian patients.
Q2: When will the new TAVR system be available?
A2: S3V plans to launch the device commercially within 12 to 18 months, pending successful trials and regulatory approvals.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
S3V Vascular Technologies moves its indigenous TAVR system into preclinical trials to lower costs and improve access to cardiac care for Indian patients....
5 months ago
Percutaneous tricuspid valve-in-valve implantation provides a life-saving, minimally invasive approach for high-risk patients experiencing severe bioprosthetic tricuspid valve failure and refractory right heart failure after multiple cardiac surgeries.
Today
A probabilistic sensitivity analysis demonstrates that single-sample reflex testing maintains superior thalassemia screening cascade efficiency over multivisit protocols, eliminating patient dropout and boosting cost-effectiveness across diverse operational scenarios.
Today
A comprehensive review of how mitochondrial omics decodes macrophage foam cell formation and metabolic reprogramming in atherosclerosis, highlighting novel diagnostic and therapeutic targets for cardiovascular medicine.
Today
A breakthrough study reveals how the agricultural fungicide thiram disrupts hepatic and tibial calcium homeostasis through ER stress and IP3R1/VDAC1 hyperactivation, uncovering a critical liver-bone axis of systemic toxicity.
Today
A study in children with severe acute malnutrition reveals disordered pancreatic and gut hormone responses to nutrient stimulation, including elevated basal insulin and blunted postprandial surges. These findings emphasize the need for refined nutritional rehabilitation protocols to prevent metabolic complications.
Today
